Webinar: Overcoming scFv Instability with Opti-mAb®
We invite you to a joint webinar by AAX Biotech AB and evitria AG: “Accelerating multispecific antibody development: Overcoming scFv instability with Opti-mAb®”
Engineering multispecific antibodies often means working with single-chain variable fragments (scFvs)—elegant in design, but challenging in practice. Aggregation, low expression, and instability frequently impair manufacturability and delay lead selection. Join AAX Biotech and evitria AG for an exclusive look at brand-new comparative data. We will demonstrate how our proprietary molecular stabilization technology, Opti-mAb®, stabilizes scFv-containing formats, from simple bispecifics to complex multi-chain architectures, when paired with evitria's high-throughput CHO transient expression platform.
Event Details
📅Date: Tuesday, November 3, 2026
⏰Time: 3pm CET
🕙Duration: 45 minutes
🎤Speakers: Daniel X. Johansson, CEO/CSO at AAX Biotech & Julia Pizzolato, Commercial Scientific Liaison at evitria AG
What You Will Learn
Part 1: In the first part of the webinar, Daniel X. Johansson, CEO/CSO at AAX Biotech, will introduce the stability issues of scFvs that led to the development of Opti-mAb® and present the improvements in yield, aggregation and stability that Opti-mAb® brings to scFvs, scFv-containing bispecifics (Blinatumomab) and CAR-T.
Part 2: In the second part, Julia Pizzolato from evitria AG will present the results of testing Opti-mAb® in three different, more complex asymmetric bi- and trispecific formats that had previously shown significant aggregate formation upon expression.